生物制药公司Nuvalent, Inc.宣布，已正式向美国食品药品监督管理局（FDA）提交了其研究性药物Neladalkib的新药申请（NDA）。该申请旨在寻求批准Neladalkib用于治疗既往接受过酪氨酸激酶抑制剂（TKI）治疗的间变性淋巴瘤激酶（ALK）阳性晚期非小细胞肺癌（NSCLC）患者。
这一重要监管里程碑标志着该药物在开发进程中迈出了关键一步，若获批准，将为这类患者群体提供一个新的潜在治疗选择。
生物制药公司Nuvalent, Inc.宣布，已正式向美国食品药品监督管理局（FDA）提交了其研究性药物Neladalkib的新药申请（NDA）。该申请旨在寻求批准Neladalkib用于治疗既往接受过酪氨酸激酶抑制剂（TKI）治疗的间变性淋巴瘤激酶（ALK）阳性晚期非小细胞肺癌（NSCLC）患者。
这一重要监管里程碑标志着该药物在开发进程中迈出了关键一步，若获批准，将为这类患者群体提供一个新的潜在治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.